On December 25th, 2025, RabPharma Biopharma Co., Ltd. (“RabPharma”) announced that the Investigational New Drug (IND) application for a new indication of its core pipeline candidate, RAB001 for injection, has been approved by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The newly approved indication expands the clinical development of RAB001 into knee osteoarthritis, marking the second IND approval obtained for this innovative bone regenerative therapy. The IND approval (Acceptance No. CXHL2501164) represents an important milestone in broadening the clinical application of RAB001 from osteonecrosis to osteoarthritis, one of the world’s most prevalent degenerative musculoskeletal diseases.

Baheal Pharma Group has been named among the "Top 30 Strategic Investors / CVCs in China" in Zero2IPO Research Center's 2025 China Venture Capital & Private Equity Annual Ranking, reflecting the Group’s sustained commitment and proven track record in healthcare innovation investment and incubation.

Baheal Medical (301015.SZ) is accelerating the implementation of its integrated radiotherapy strategy centered on precision oncology technologies, building a full-cycle ecosystem encompassing global technology introduction, China-based manufacturing for worldwide supply, precision radiotherapy center development, and evidence-based clinical research. Between 5th-9th December 2025, Baheal announced a series of major milestones surrounding the ZAP-X® Gyroscopic Radiosurgery System, including the launch of a global manufacturing and supply center, the initiation of large-scale clinical studies, and the continued expansion of precision radiotherapy centers in China. Together, these developments mark a new stage of large-scale, standardized clinical adoption of ZAP-X in China and reflect the accelerating execution of Baheal's long-term radiotherapy strategy.

Baheal Medical (301015.SZ), in collaboration with Xuanwu Hospital Capital Medical University, has officially launched an Investigator Initiated Trial (IIT) focused on the clinical application of ZAP-X Gyroscopic Radiosurgery System in brain metastases. The study was announced during the Academic Forum of the Chinese Intracranial Metastasis Alliance (CLAIM) held on December 8, 2025. The IIT study is led by Professor Zhang Hongqi, Director of Neurosurgery at Xuanwu Hospital, and aims to further evaluate the clinical efficacy, safety, and dosimetric characteristics of ZAP-X for patients with brain metastases.

On December 6, 2025, Baheal Pharma Group announced the official launch of its “Baheal Pharma Group High-End Manufacturing Industrialization Base” located in the Daxing International Airport Economic Zone (Langfang). This base also serves as ZAP Surgical’s global manufacturing center in China, marking a major step toward large-scale production of the ZAP-X Gyroscopic Radiosurgery™ System, a leading precision radiotherapy device for brain tumors, enabling “Made in China, Delivered Globally.” The ceremony was attended by Hou Xiaoping, Member of the Standing Committee of the CPC Langfang Municipal Committee and Executive Vice Mayor of Langfang; Ding Ling, Vice Mayor of Langfang and Party Secretary and Director of the Administrative Committee of the Langfang Airport Economic Zone; Fu Gang, Chairman of Baheal Pharma Group; Zhu Xiaowei, Vice President of Baheal Medical; and Dr. John R. Adler, Founder and CEO of ZAP Surgical, along with other distinguished guests.